Emerald gains exclusive worldwide development rights to ESS, MANF and PhenoGuard Amarantus receives Emerald preferred stock valued at a minimum of $66.6 million New York, NY, Jan. 02, 2020 (GL...
02
Jan
Portfolio includes treatments for Alzheimer's disease, ADHD, Parkinson's disease, vision loss and severe burns Amarantus to receive Emerald Organics Preferred Stock for the exclusive worldwide lice...